Skip to content

ACT-DE for Diabetes Distress in Adults With Type 2 Diabetes: A Pilot RCT

The Effects of an Acceptance-based Diabetes Education (ACT-DE) Programme for Adults With Type 2 Diabetes on Diabetes Distress: a Pilot RCT

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05563987
Acronym
ACT-DE
Enrollment
48
Registered
2022-10-03
Start date
2021-10-01
Completion date
2022-03-30
Last updated
2022-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acceptance and Commitment Therapy, Diabetes Distress, Type 2 Diabetes

Brief summary

This study is a pilot RCT to examine the feasibility, acceptability and preliminary effectiveness of a 6-week acceptance-based diabetes education programme (ACT-DE) on diabetes distress, self-care efficacy and behaviours of adults with type 2 diabetes in Hong Kong. It is hypothesise that the ACT-DE programme will: * Be acceptable, feasible and beneficial for adults with type 2 diabetes to improve their psychological distress and self-care. * Significantly reduce participants' diabetes distress (primary outcomes), when compared with the usual care (control) group immediately post-intervention; * Significantly improve self-care efficacy, self-care behaviour and psychological flexibility (secondary outcomes) than the control group immediately post-intervention.

Detailed description

Diabetes distress is an aversive feeling and emotional disturbance specific to diabetes, including the burden of daily self-care, worry and guilty feelings, and low satisfaction level with health care professionals. Around 36% of people with type 2 diabetes worldwide suffered from diabetes distress, which is associated with poor self-care performance, low self-efficacy in diabetes management and higher blood glucose levels. Acceptance and Commitment Therapy, one of the mindfulness and acceptance-based interventions, integrated with diabetes education are found to be potentially effective interventions for reducing diabetes distress. Participants who agreed to participate in the study were randomly allocated into the intervention (N=24) and the control group (N=24). Participants in the intervention group received a 6-week group-based acceptance and commitment therapy integrated with diabetes education (ACT-DE). There were five sessions in 6 weeks with 120 minutes per session. The group size were 6. While participants in the control group received one session of diabetes education without any information on acceptance and commitment therapy.

Interventions

BEHAVIORALACT-DE

The acceptance and commitment therapy is a psychological component to cultivate participants' acceptance attitude to diabetes and motivate them for a value-driven persistent diabetes self-management, directed by six psychological processes in the hexagonal model of ACT, including acceptance, cognitive defusion, the present moment, self-as-context, value clarification and committed action.

BEHAVIORALDE

DE

Sponsors

Chinese University of Hong Kong
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

The outcome assessor who is responsible for collecting outcome data and data entry has no idea about the group allocation of participants.

Intervention model description

Participants were random allocated (1:1 ratio) to either the intervention group that received a 6-week (5 sessions) group-based ACT-DE programme. While participants in the control group received 1 session of diabetes education.

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* community-dwelling adults Hong Kong Chinese residents, * aged 18-64, * diagnosed with type 2 diabetes for over one year; * at least moderate level of diabetes distress as measured with the Chinese Diabetes Distress Scale (CDDS-15; mean score \>2 per item); * having suboptimal blood glucose control as shown by HbA1c level of ≥ 7% in the laboratory results within the past six months; * able to communicate in Cantonese and give written content.

Exclusion criteria

* history of a clinically diagnosed mental illness such as depression and anxiety disorder, and/or an acute/severe medical disease; * noticeable cognitive impairment(s) as indicated by the total score (\<6 of 10) of the Abbreviated Mental Test; * recently received/receiving any psychological therapy such as mindfulness or acceptance-based therapy.

Design outcomes

Primary

MeasureTime frameDescription
Change in Diabetes Distress Scalebaseline (T0) and immediate post-intervention (T1)Diabetes distress was measured by the Chinese 15-item Diabetes Distress Scale (CDDS-15). It consists of 15 items rated on a six-point Likert scale from 1 = 'not a problem' to 6 = 'a serious problem'. A mean item score of 2-2.9 and ≥3.0 indicates moderate and severe distress, respectively.

Secondary

MeasureTime frameDescription
Diabetes self-management behavioursbaseline (T0) and immediate post-intervention (T1)was measured by the Chinese version of diabetes self-management activities (C-SDSCA). It has 11-items rated on an eight-point Likert scale from 0 to 7, with higher scores indicating more attention to self-management activities.
Diabetes management self-efficacybaseline (T0) and immediate post intervention (T1)was measured by the Chinese version of Diabetes Management Self-Efficacy Scale (C-DMSES). The C-DMSES contains 20 items rated on an 11-point Likert scale, in which zero indicates not at all confident, and 10 indicates very confident.
Psychological flexibilitybaseline (T0) and immediate post-intervention (T1)was measured by the Chinese version of the Acceptance and Action Questionnaire (AAQ-II Chinese). It contains seven items rated on a seven-point, agreement-based response scale from 1 = 'never true' to 7 = 'always true'. The AAQ-II will be scored by summing all item responses, with higher scale scores indicating a greater psychological inflexibility.

Countries

Hong Kong

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026